The current subscription period is extended to July 17
The Board of Cline Scientific AB has decided to extend the subscription period in the ongoing rights issue. The extension applies until Monday 17 July 2023. A further SEK 1.5 million is required to reach SEK 5.5 million.
The issue has been subscribed to SEK 4 million, however the minimum limit to complete the issue was set to SEK 5.5 million. The management is therefore working on bringing in additional capital to reach the level of SEK 5.5 million.
For those who want to participate in the issue, there is an opportunity by sending in a subscription form to info@nordic-issuing.se. Subscription notes can be found on Nordic Issuing's website www.nordic-Issuing.se.
"We are grateful to everyone who subscribed to the rights issue. Our minimum target has not been met, however not much is missing. Therefore, we choose to extend the subscription period for a couple more days and work hard to bring in the last capital.” Hanne Evenbratt, CEO.
The company is listed on the Nasdaq First North Growth Market. Redeye AB is Cline Scientific's Certified Adviser.
This information is information that Cline Scientific is required to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication by the contact person set out above, at 8:42 CEST on 14/07/2023.
For more information, please contact:
Hanne Evenbratt, CEO
Email: hanne.evenbratt@clinescientific.com
Phone: +46 703-585 088
Cline Scientific AB (publ)
Pepparedsleden 1
AstraZeneca BioVentureHub Email: info@clinescientific.com
431 53 MÖLNDAL Website: www.clinescientific.com
About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline’s unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.